EUVIMEDEUVIMED entdecken
Crossref

The top 5 issues in EU medicines policy for 2018

Yannis Natsis

Medicine Access @ Point of Care · 2018

DOI: 10.1177/2399202618774510 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medicine Access @ Point of Care, 2018. Verfasst von Yannis Natsis. Die Arbeit nennt 27 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The present analysis looks at the key issues which dominate the EU medicines policy agenda during 2018 namely the proposed regulation on European collaboration on Health Technology Assessment (HTA), the ongoing discussion around the role of intellectual property related incentives in biomedical R&D, the future of initiatives such as BeNeLuxA, the role of the European Medicines Agency and the reaction of the pharmaceutical companies to the unprecedented debate around access to medicines in Europe.

Zitieren

APA

Natsis, Y. (2018). The top 5 issues in EU medicines policy for 2018. Medicine Access @ Point of Care. https://doi.org/10.1177/2399202618774510

Vancouver

Natsis Y. The top 5 issues in EU medicines policy for 2018. Medicine Access @ Point of Care. 2018. doi:10.1177/2399202618774510

BibTeX
@article{Natsis2018,
  author = {Natsis, Yannis},
  title = {The top 5 issues in EU medicines policy for 2018},
  journal = {Medicine Access @ Point of Care},
  year = {2018},
  doi = {10.1177/2399202618774510}
}
Kostenlos starten →